Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Thyroid

Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer

Brian Park, PharmD

March 2, 2021

The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.

Thyroid

Thyquidity Oral Solution Now Available for Hypothyroidism

Brian Park, PharmD

February 26, 2021

Thyquidity (levothyroxine sodium) oral solution is indicated for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Androgen and Reproductive Disorders

Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause

Brian Park, PharmD

February 25, 2021

Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.

Practice Management

Digital Health App Tracks Pain Progress With Neurostimulation Therapy

Brian Park, PharmD

February 4, 2021

Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.

Diabetes

Finerenone Gets Priority Review for Diabetic Kidney Disease

Brian Park, PharmD

January 29, 2021

The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.

Diabetes

Dapagliflozin Under Review for Chronic Kidney Disease

Brian Park, PharmD

January 12, 2021

The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.

Diabetes

FDA Approves First Generic Version of Glucagon Emergency Kit

Brian Park, PharmD

January 5, 2021

The FDA has approved the first generic equivalent of Glucagon Emergency Kit (Lilly), according to Amphastar Pharmaceuticals.

Diabetes

Tirzepatide Significantly Reduced HbA1C and Weight in Type 2 Diabetes

Brian Park, PharmD

December 15, 2020

Tirzepatide is an investigational dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule.

Androgen and Reproductive Disorders

Twirla Transdermal System Now Available for Contraception

Brian Park, PharmD

December 11, 2020

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI <30kg/m2 for whom a combined hormonal contraceptive is appropriate.

Pediatric Endocrinology

Hydrocortisone Oral Granules Approved for Pediatric Adrenocortical Insufficiency

Brian Park, PharmD

December 1, 2020

Alkindi Sprinkle contains immediate-release oral hydrocortisone granules designed for the dosing needs of pediatric patients with adrenocortical insufficiency.

Next post in Pediatric Endocrinology